Oxford Cannabinoid Technologies video with Doceo
Oxford Cannabinoid Technologies Holdings plc (OCT) have launched new video content with Doceo.
OCT is a pharmaceutical company developing prescription cannabinoid medicines for approval by global regulatory agencies and targeting the US$ multi-billion pain market. OCT aims to revolutionise drug development by utilising a diverse range of compounds, including proprietary cannabinoid derivatives, natural phytocannabinoids, and innovative new chemical entities (NCEs) that target the endocannabinoid system.
Clarissa Sowemimo-Coker, Chief Executive Officer, explains how the company is developing non-addictive, cannabinoid-based medicines. There is demand for alternatives from people living with debilitating pain conditions that are poorly served by current treatments.
For further information on Doceo please visit www.doceo.tv or contact the team on info@doceo.tv
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 18 hours ago IntegraFin Holding
- 19 hours ago Spirent Communications
- 19 hours ago CRH (CDI)
- 19 hours ago Bezant Resources
- 20 hours ago EJF Investments Ltd NPV